X. W. Trixhe

Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy

B. Burkhardt, R. Norris, A. Howes, 2020, Leukemia.

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Xavier Woot de Trixhe, J. Byrd, G. Nicolao, 2014, Cancer Chemotherapy and Pharmacology.

Abstract B19: Population pharmacokinetic-pharmacodynamic (PKPD) modeling of ibrutinib in patients with B-cell malignancies.

Michael L. Wang, J. Byrd, G. Nicolao, 2015 .

Dynamic simulation and steady-state computation of 3D physiologically structured population models

Michiel Van Dyck, Wim Vanroose, X. W. Trixhe, 2018 .

PHARMACOKINETIC DYNAMIC RELATIONSHIPS Dynamic population pharmacokinetic – pharmacodynamic modelling and simulation supports similar ef fi cacy in glycosylated haemoglobin response with once or twice-daily dosing of canagli fl ozin

W. Winter, J. Pinheiro, Chyi-Hung Hsu, 2017 .

vRNA structured population model for Hepatitis C Virus dynamics.

F. De Ridder, A. Vermeulen, W. Krzyzanski, 2015, Journal of theoretical biology.

Modelling the impact of JNJ-1802, a first-in-class dengue inhibitor blocking the NS3-NS4B interaction, on in-vitro DENV-2 dynamics

I. Dorigatti, Peggy Geluykens, Doortje Borrenberghs, 2023, PLoS Comput. Biol..